Crown Laboratories Acquires Keri Brand from GlaxoSmithKline
May 1, 2019
Crown Laboratories acquired the North American rights to the Keri skin care brand from GlaxoSmithKline and concurrently received an equity investment from Greenspring Associates. Existing investors Hildred Capital Partners and Montreux Equity Partners provided financing in connection with the transaction; financial terms were not disclosed.
- Buyers
- Crown Laboratories, Inc., Greenspring Associates, Inc., Hildred Capital Partners, LLC, Montreux Equity Partners, LLC
- Targets
- Keri
- Sellers
- GlaxoSmithKline
- Industry
- Consumer Products
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
KYT Group Acquires Glo Skin Beauty
March 3, 2026
Consumer Products
KYT Group and its institutional investment partners acquired premium, clean and clinically rooted skincare brand Glo Skin Beauty to support focused, long-term growth. The deal includes an operator-led leadership transition, with KYT Co-Founder and Managing Partner Kurt Kober assuming CEO.
-
Crown Laboratories Acquires Revance Therapeutics in $924M Merger
August 12, 2024
Healthcare Services
Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. for $6.66 per share in cash, representing an enterprise value of $924 million. The deal closed after Crown commenced a tender offer and then completed a second-step merger, with Revance becoming wholly owned by Crown and delisted from Nasdaq.
-
Crown Laboratories Acquires Eclipse Medcorp's Aesthetics Assets
May 24, 2022
Medical Devices
Crown Laboratories has acquired the global, aesthetics-focused assets of Eclipse Medcorp, LLC, expanding Crown's aesthetics product portfolio and integrating Eclipse's devices into its Aesthetics business unit. The deal aims to broaden Crown's product offerings to aesthetics providers domestically and internationally and preserve service and medical-education support for Eclipse customers under Crown.
-
Crown Laboratories Acquires StriVectin from L Catterton
August 26, 2021
Consumer Products
Crown Laboratories, a Hildred Capital portfolio company, has entered into a definitive agreement to acquire StriVectin from L Catterton. StriVectin will operate as a wholly owned subsidiary within Crown's new Premium Skincare Division, with its president Cori Aleardi joining Crown's executive team; the deal was expected to close by mid-September 2021.
-
Crown Capital Investments Acquires KCE, Inc.
February 21, 2020
Trucking & Fleet
Crown Capital Investments, LLC, an Atlanta-based family office, has acquired KCE, Inc., a Glen St. Mary, Florida specialist in oversized load transportation, erosion control and proprietary water cleanup. The acquisition positions Crown Capital to grow KCE ahead of anticipated U.S. infrastructure investment and to optimize the company’s operations and capabilities.
-
Crown Laboratories Acquires Xycrobe Therapeutics, Inc.
May 22, 2019
Biotechnology
Crown Laboratories, a privately held skin care company based in Johnson City, Tennessee, has acquired Xycrobe Therapeutics, a developer of skin microbiome-based biotherapeutic technology. Crown plans to integrate Xycrobe’s microbiome platform and scientific team into its R&D organization to expand therapeutic and consumer skin-care capabilities; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.